The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR)

• Published in: BMC medical research methodology Vol. 24; no. 1; pp. 102 - 11
• Main Authors: Aoki, Naomi, Chen, Pin-Yen, Chen, Wenming, Chng, Wee Joo, Gan, Gin Gin, Goh, Yeow Tee, Hou, Jian, Huang, Jeffrey, Kim, Kihyun, Lee, Je Jung, Lu, Jin, McQuilten, Zoe K., Min, Chang Ki, Moore, Elizabeth, Oliver, Laura, Waters, Neil A., Wellard, Cameron, Wood, Erica M., Yeh, Su-Peng, Spencer, Andrew
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.05.2024; BioMed Central; BMC
• Subjects: Asia - epidemiology; Blood cancer; Care and treatment; Clinical medicine; Clinical registry; Clinical trials; Consent; Data collection; Diagnosis; Epidemiology; Female; Health care access; Hospitals; Humans; Immunotherapy; Inhibitor drugs; Leukemia; Lymphomas; Malaysia - epidemiology; Male; Medical research; Medicine, Experimental; Middle Aged; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - epidemiology; Multiple Myeloma - therapy; Patient outcomes; Patients; Privacy; Prospective Studies; Quality of life; Real-world data; Registries (in medicine); Registries - statistics & numerical data; Republic of Korea - epidemiology; Services; Singapore - epidemiology; Taiwan - epidemiology; Targeted cancer therapy; Malaysia; Singapore; Asia; Republic of Korea; Taiwan; South Korea; China; East Asia; Uganda; Australia; Pacific Rim; Canada; United States > US; Pacific region; Europe; Clinical registry; Epidemiology; Multiple myeloma; Real-world data

Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM incidence is rising, yet it remains incurable and represents a significan...